SuperworthEli Lilly and profit margin LLY
Gross, operating and net profit as a share of revenue over the last twelve months, from 1995.
- Net margin, 12 months
- 33.5%
- Operating margin, 12 months
- 42.2%
- Net margin on a year earlier
- +7.6 pts
- Peer median
- 8.3%
Over the twelve months to Jun 30, 2026, Eli Lilly and kept 33.5% of its revenue as net profit, with an operating margin of 42.2% and a gross margin of 83.4%.
Five years earlier its net margin was 22.7%.
The median for 7 large drugmakers of a similar size is 8.3%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 31.7% | 40.4% | 83.0% |
| FY2024 | 23.5% | 28.6% | 81.3% |
| FY2023 | 15.4% | 18.9% | 79.2% |
| FY2022 | 21.9% | 25.0% | 76.8% |
| FY2021 | 19.7% | 22.4% | 74.2% |
| FY2020 | 25.2% | 24.7% | 77.7% |
| FY2019 | 37.3% | 22.3% | 78.8% |
| FY2018 | 15.0% | 16.4% | 78.2% |
| FY2017 | −0.9% | 8.3% | 73.1% |
| FY2016 | 12.9% | 16.3% | 73.4% |
| FY2015 | 12.1% | 13.5% | 74.8% |
| FY2014 | 12.2% | 13.6% | 74.9% |
| FY2013 | 20.3% | 23.2% | 78.8% |
| FY2012 | 18.1% | 20.9% | 78.8% |
| FY2011 | 17.9% | 22.8% | 79.1% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 33.5% | +7.6 pts | 42.2% | |
| Q1 FY26 | 35.0% | +12.3 pts | 43.6% | |
| Q4 FY25 | 31.7% | +8.2 pts | 40.4% | |
| Q3 FY25 | 31.0% | +10.5 pts | 38.8% | |
| Q2 FY25 | 25.9% | +7.0 pts | 32.4% | |
| Q1 FY25 | 22.7% | +5.6 pts | 28.7% | |
| Q4 FY24 | 23.5% | +8.2 pts | 28.6% | |
| Q3 FY24 | 20.5% | +4.9 pts | 24.8% | |
| Q2 FY24 | 18.9% | −3.2 pts | 23.3% | |
| Q1 FY24 | 17.1% | −3.5 pts | 20.8% | |
| Q4 FY23 | 15.4% | −6.5 pts | 18.9% | |
| Q3 FY23 | 15.6% | −5.1 pts | 18.4% |
Against its peers
Companies in Drug Manufacturers - General nearest Eli Lilly and's size, closest first, today.
| Company | Profit margin |
|---|---|
| LLYEli Lilly and | 33.5% |
| JNJJohnson & Johnson | n/m |
| ABBVAbbVie | 9.8% |
| MRKMerck | 4.8% |
| AMGNAmgen | 23.0% |
| GILDGilead Sciences | −10.6% |
| PFEPfizer | 6.8% |
| BMYBristol-Myers Squibb | 18.9% |
| Peer median | 8.3% |
Where Eli Lilly and ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Eli Lilly and
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.